Business

Commercial launch of low priced COVID-19 test approved by DGCI

The Drugs Controller General of India has approved the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) has said.

migrator

New Delhi

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement. The test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology). 

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

IUML snaps six-decade-old ties with DMK, seeks larger role in TVK-led govt, alliance

Peace talks with Iran on track; Witkoff, Kushner in Switzerland: Vance

Rain ruins 1.50 lakh paddy bags; Kumbakonam ryots flay officials' apathy

Pro-TVK Assembly clips erode House dignity, says LoP

ISL 2026-27 to start on September 4